Claims for Patent: 7,491,725

Summary for Patent: 7,491,725

Title:	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Abstract:	The invention relates to processes for preparing compounds having the formula, and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R2, R3, R4, and R5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
Inventor(s):	Jean Lajeunesse, John D. DiMarco, Michael Galella, Ramakrishnan Chidambaram
Assignee:	Bristol Myers Squibb Co
Application Number:	US11/192,867
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,491,725
Patent Claims:	1. Crystalline monohydrate of the compound of formula (IV) which is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1. 2. The compound of claim 1, which is characterized by differential scanning calorimetry thermogram and a thermogravimetric anaylsis substantially in accordance with that shown in FIG. 2. 3. Crystalline monohydrate of the compound of formula (IV) which is characterized by an x-ray powder diffraction pattern (CuKα γ=1.5418 Å at a temperature of about 23° C.) comprising four or more 2θ values selected from the group consisting of: 18.0±0.2, 18.4±0.2, 19.2±0.2, 19.6±0.2, 21.2±0.2, 24.5±0.2, 25.9±0.2, and 28.0±0.2. 4. A solid pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 3 and a pharmaceutically acceptable carrier. 5. The compound of claim 3, characterized by unit cell parameters approximately equal to the following: Cell dimensions: a(Å)=13.8632(7); b(Å)=9.3307(3); c(Å)=38.390(2); Volume=4965.9(4) Å3 Space group Pbca Molecules/unit cell 8 Density (calculated) (g/cm3) 1.354. 6. A process for preparing the compound of claim 3 comprising heating and dissolving the compound of formula (IV) in an ethanol/water mixture and crystallizing the monohydrate from the ethanol/water mixture as it cools. 7. The process of claim 6, wherein a butanol solvate of the compound of formula (IV) is dissolved in the ethanol/water mixture. 8. The compound of claim 3, wherein the compound is substantially pure. 9. The compound of claim 3, the compound being further characterized by a differential scanning calorimetry having a broad peak between approximately 95° C. and 13° C. which corresponds to the loss of one water of hydration on thermogravitmetric analysis. 10. The compound of claim 9, which is further characterized by a weight loss of 3.48% by thermogravimetric analysis between 50° C. and 175° C. 11. The compound of claim 9, wherein the differential scanning calorimetry further has a peak at approximately 287° C. 12. Crystalline monohydrate of the compound of formula (IV) which is characterized by a differential scanning calorimetry having a broad peak between approximately 95° C. and 130° C. which corresponds to the loss of one water of hydration on thermogravitmetric analysis. 13. A solid pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 12 and a pharmaceutically acceptable carrier. 14. A solid pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 9 and a pharmaceutically acceptable carrier. 15. The compound of claim 12, wherein the compound is substantially pure. 16. The compound of claim 9, wherein the compound is substantially pure. 1. Crystalline monohydrate of the compound of formula (IV) ##STR00061## which is characterized by an x-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1. 2. The compound of claim 1, which is characterized by differential scanning calorimetry thermogram and a thermogravimetric anaylsis substantially in accordance with that shown in FIG. 2. 3. Crystalline monohydrate of the compound of formula (IV) ##STR00062## which is characterized by an x-ray powder diffraction pattern (CuK.alpha. .gamma.=1.5418 .ANG. at a temperature of about 23.degree. C.) comprising four or more 2.theta. values selected from the group consisting of: 18.0.+-.0.2, 18.4.+-.0.2, 19.2.+-.0.2, 19.6.+-.0.2, 21.2.+-.0.2, 24.5.+-.0.2, 25.9.+-.0.2, and 28.0.+-.0.2. 4. A solid pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 3 and a pharmaceutically acceptable carrier. 5. The compound of claim 3, characterized by unit cell parameters approximately equal to the following: Cell dimensions: a(.ANG.)=13.8632(7); b(.ANG.)=9.3307(3); c(.ANG.)=38.390(2); Volume=4965.9(4) .ANG..sup.3 Space group Pbca Molecules/unit cell 8 Density (calculated) (g/cm.sup.3) 1.354. 6. A process for preparing the compound of claim 3 comprising heating and dissolving the compound of formula (IV) in an ethanol/water mixture and crystallizing the monohydrate from the ethanol/water mixture as it cools. 7. The process of claim 6, wherein a butanol solvate of the compound of formula (IV) is dissolved in the ethanol/water mixture. 8. The compound of claim 3, wherein the compound is substantially pure. 9. The compound of claim 3, the compound being further characterized by a differential scanning calorimetry having a broad peak between approximately 95.degree. C. and 13.degree. C. which corresponds to the loss of one water of hydration on thermogravitmetric analysis. 10. The compound of claim 9, which is further characterized by a weight loss of 3.48% by thermogravimetric analysis between 50.degree. C. and 175.degree. C. 11. The compound of claim 9, wherein the differential scanning calorimetry further has a peak at approximately 287.degree. C. 12. Crystalline monohydrate of the compound of formula (IV) ##STR00063## which is characterized by a differential scanning calorimetry having a broad peak between approximately 95.degree. C. and 130.degree. C. which corresponds to the loss of one water of hydration on thermogravitmetric analysis. 13. A solid pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 12 and a pharmaceutically acceptable carrier. 14. A solid pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 9 and a pharmaceutically acceptable carrier. 15. The compound of claim 12, wherein the compound is substantially pure. 16. The compound of claim 9, wherein the compound is substantially pure.